Background: The objective of this study was to investigate cardiovascular disease risk factor (cvRF) profiles and compare their trends over 17 years in patients with and without acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Hypothesis: Time trends of cvRF are different between ACS and non-ACS patients. Methods: This study was a time-trend analysis from 1994 to 2010 within the Mayo Clinic PCI registry. Outcome measures were incidence and prevalence of cvRF, including the Framingham Risk Score (FRS), at the time of admission for PCI. Results: Age of non-ACS patients was higher than that of ACS patients, and age distribution slightly shifted toward older age in both groups (P for trend <0.001). There was no difference in FRS between the 2 groups; however, 10-year cardiovascular disease risk (%) remained higher in non-ACS than in ACS patients, decreasing over time. Diastolic blood pressure and high-density lipoprotein cholesterol were higher in non-ACS patients, but total cholesterol and low-density lipoprotein cholesterol were higher in ACS patients, with an improving trend over time. Prevalence of diabetes mellitus, hypertension, and history of hypercholesterolemia were higher in non-ACS patients, increasing over time. Smoking did not change over time. Use of most medications increased over time in both groups. Conclusions: Most cvRFs and their time trends exhibited statistically significant differences between ACS and non-ACS patients, except systolic blood pressure, body mass index, and history of myocardial infarction. A new risk-factor profile assessment may be needed for stratification of PCI patients according to ACS and non-ACS status. Clinical and public-health interventions should consider different approaches to ACS and non-ACS patients.
Introduction
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide. 1 In 2007, one-quarter of all deaths in the United States were from diseases of the heart. In developing countries, morbidity and mortality attributed to CVD are increasing due to rapid demographic, socioeconomic, and lifestyle transitions. In
The authors have no funding, financial relationships, or conflicts of interest to disclose. developed countries, although the mortality rate from CVD has decreased over the past 2 decades, driven by decreases in tobacco use and saturated-fat consumption, better control of CVD risk factors (cvRFs), and better clinical management of acute coronary disease, 2 the morbidity burden remains high and CVD is still the leading cause of premature death in these countries. 3, 4 Understanding the change of major cvRFs is important for the primary, secondary, and tertiary prevention of CVD. Community-based epidemiologic studies are often excluded from clinical practice because of their limited clinical utility. 5, 6 It is meaningful to understand the changes of cvRFs and Framingham Risk Score (FRS) in patients undergoing percutaneous coronary intervention (PCI), because PCI is one of the major treatments affecting the outcome of CVD. Moreover, assessing various trends of the pathology adds to and enables personalized treatments in CV medicine. However, there is a paucity of data on temporal trends in cvRF profiles, 7 and assessing comparable improvements occurring in PCI patients remains challenging, especially in PCI patients with hospitalization.
Acute coronary syndromes (ACS) are acute symptomatic myocardial ischemia caused by a coronary plaque rupture and subsequent intracoronary thrombosis formation, mostly associated with chronic coronary atherosclerosis. Clinical consequences of ACS are variable, ranging from minimal complications to early death. Thus, necessitating early pharmacological treatment and revascularization of one or more diseased coronary arteries either percutaneously or surgically. 8 The term ACS describes myocardial ischemia resulting from various causes (unstable angina pectoris [UA] or myocardial infarction [MI] , with or without concomitant ST-segment elevation). 9 In contrast, stable angina is a chronic condition of regional myocardial ischemia caused by inadequate coronary perfusion, usually induced by increase in myocardial oxygen requirements like physical exertion and which is relieved by rest and/or nitroglycerin. 10 Therefore, cvRFs and FRS in PCI patients may differ based on ACS vs non-ACS status. Also, medical and interventional treatments might have different outcomes based on the 2 latter groups.
Thus, this study was aimed to examine 17-year trends in cvRFs and the FRS in patients undergoing PCI with and without ACS in the hospital-based retrospective design to assess differences between ACS and non-ACS in rate of risk factors over time. Also, our study provides a comprehensive view of PCI patients at Mayo Clinic over time.
Methods
We analyzed data of all PCI patients included into the Mayo Clinic PCI Registry in Rochester, Minnesota, in the time period from January 1, 1994, to December 31, 2010. Patients undergoing PCI are prospectively followed in a registry that includes demographic, clinical, angiographic, and procedural data. Immediate and in-hospital events were recorded, and each patient is surveyed by telephone using a standardized questionnaire at 6 months and 1 year, and then annually after the procedure. Ten percent of all records are randomly audited by the supervisor for data integrity. Relevant clinical information was abstracted from medical records. For patients with multiple PCIs within a single hospitalization, only the first PCI of that hospitalization was included. There were 26 172 PCI hospitalizations of 20 711 unique patients during this period. Five hundred thirty patients refused authorization of their records for research and were excluded; therefore, 25 519 hospitalizations were used for analysis. This study was approved by the Mayo Clinic Institutional Review Board.
Data retrieved from the PCI Registry included general patient characteristics (hospital ID, date, age, sex, and family history of heart disease), diagnostic information (ACS, including ST-segment elevation MI [STEMI], non-STEMI, and UA), and cvRF profiles (smoking status, presence of diabetes mellitus [DM] , hypertension, hypercholesterolemia, height, weight). 11 Medications used included aspirin, β-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and lipid-lowering drug at baseline (within 3 days prior to PCI) and on discharge. Hypercholesterolemia was defined as total cholesterol (TC) ≥240 mg/dL. Presence of hypertension was defined as a documented history of hypertension that has been treated with medication. History of MI was defined as MI that occurred ≥7 days prior to PCI. Cholesterol and blood pressure values were retrieved from electronic medical records. Blood pressure values within 2 years before and 2 months after PCI were acceptable; if multiple measures were found, the measure occurring on the date closest to PCI was recorded. These data were used to calculate estimated risk of CAD using the FRS sheet. 12 Continuous variables are presented as mean ± SD or as median (quartile 1, quartile 3). Discrete data are presented as frequencies and percentages. We classified the patients into 3 groups based on the date of PCI for the statistical analysis of trends. The first group included patients who had PCI from 1994 to 1999, the second group included PCIs from 2000 to 2005, and the third group included PCIs from 2006 to 2010. Analysis of variance with a linear contrast analysis was used to assess the trend of continuous variables, and the Cochran-Armitage trend test was used for comparison of proportions both overall and within the ACS and non-ACS groups. Additionally, using linear regression for continuous variables and logistic regression for binary variables, we tested whether the linear trend over time for ACS and non-ACS was identical by testing for an interaction between groups and time. Statistical analysis was performed with SAS version 9.2 (SAS Institute, Inc., Cary, NC). All hypothesis tests were 2-tailed with a statistical significance level of P < 0.05.
Results
Between 1994 and 2010, PCI patients with and without ACS represented 14 886 (58.3%) and 10 633 (41.7%), respectively, of the entire PCI population of 25 519 during that time at the Mayo Clinic. Clinical characteristics and trends of the FRS and its components of the 25 519 patients in the 3 time periods are presented in Table 1 .
Mean patient age (SD) was 65.0 (12.4) years; 8125 (67%) were male. Age was higher over time in non-ACS patients compared with ACS patients (Figure 1 ). Age distribution slightly shifted toward older age in both groups (P for trend <0.001), but sex distribution was not changed over time.
Framingham Risk Score and 10-year cardiovascular risk increased over time from 1994 to 1999, decreased from 2000 to 2006, and then slightly increased again from 2006 to 2010. Overall during this period, there was a trend toward decreasing FRS and 10-year cardiovascular risk in both groups (P for trend <0.001). The FRS was not significantly different between the 2 groups; however, 10-year CVD risk remained higher in non-ACS patients compared with ACS patients while decreasing over time (P for trend = 0.008; Figure 1 ). Blood pressure and lipid profiles showed an improving trend in both groups (P for trend <0.001 for each). Systolic blood pressure did not show a difference between the 2 groups, but DBP was higher in non-ACS patients with decreasing trends over time (P for trend <0.001, P for trend <0.001 between groups). Total cholesterol and LDL-C were higher over time in ACS patients compared with non-ACS patients, with decreasing trends over time (P for trend <0.001, P for trend <0.001 between groups). The HDL-C was higher over time in non-ACS patients compared with ACS patients, with increasing trends over time (P for trend <0.001, P for trend <0.001 between groups; Figure 1 ).
However, body mass index (BMI), history of hypercholesterolemia, presence of hypertension, and DM showed an increasing trend (P for trend <0.001). Hypertension, DM, and history of hypercholesterolemia were higher in non-ACS patients over time compared with ACS patients (P for trend <0.001, P for trend <0.001 between groups). As expected, BMI demonstrated an increasing trend in both groups (P for trend <0.001), and there was no trend difference between the 2 groups (Table 1, Figure 1 ).
Prevalence of current smoking in the ACS cohort increased over time (P for trend <0.001) and the trend was higher than in non-ACS cohort over time (P for trend <0.001 between groups). In the non-ACS cohort, prevalence of current smoking exhibited a decreasing trend over time (P for trend <0.001; Figure 1) .
We examined trends in the proportion of patients treated with different classes of pharmacological agents over time. The use of most of medications increased over time in both groups (P for trend <0.001); however, β-blockers dramatically declined after 2007, as did ACEIs after 2006, both at baseline and at discharge. At baseline, use of ACEIs and lipid-lowering drugs was higher over time in non-ACS patients compared with ACS patients, with increasing trends over time (P for trend <0.001, P for trend <0.001 between groups). Similarly, at discharge, use of β-blockers and lipidlowering drugs was higher over time in ACS patients compared with non-ACS patients, with increasing trends over time (P for trend <0.001, P for trend <0.001 between groups; Table 2, Figure 2) . Figure 3 illustrates the average points contributed to the total FRS for each component in patients undergoing PCI from 1994 to 2010. Figure 3A shows total patients and Figure 3B indicates ACS and non-ACS patients. In the leftsided plots of Figure 3 , age was pretty flat, so including it makes it more difficult to see the trends in the other variables. In the right-sided plots of Figure 3 , age was left off. These results showed the different contribution of risk factors each year. When we considered the changes in each risk factor's contribution to FRS over time, we found that the improving FRS trend over time was driven by HDL-C and BP among total patients. We found remarkably different contributions of each of the components between ACS and non-ACS patients ( Figure 3B ). The contribution of DM was highest in non-ACS patients compared with ACS patients ( Figure 3B ). there is a paucity of data regarding temporal trends of cvRFs for PCI patients, particularly those with and without ACS. Therefore, we sought to investigate and compare trends of cvRF profiles over 17 years in patients with and without ACS undergoing PCI.
This study showed that FRS and 10-year CVD risk declined over time, and most cvRFs exhibited a significantly different trend in ACS patients compared with non-ACS patients, except trends in SBP, BMI, and history of MI, where the trends correlated well across both groups. These findings suggest that it might be appropriate to use different risk-factor criteria in ACS vs non-ACS patients. The FRS is the most commonly used measure worldwide for estimating individuals' 10-year risk of CVD 13 ; however, despite the established utility of the FRS, it may have limitations in certain patient populations.
14 Because the FRS assesses risk in the general population, patients who have undergone PCI will have a higher FRS than the general population. The risk factors for acute as opposed to chronic coronary disease are unclear, 15 and similarly, there is significant variation in the association between risk factors and ACS across populations. 16 -19 This study has identified 2 noteworthy findings: (1) in ACS patients, TC and LDL-C were significantly higher than in non-ACS patients, and HDL-C and prevalence of current smoking were significantly lower in ACS patients compared with non-ACS patients; and (2) in non-ACS patients, age, DBP, DM, history of high BP, and history of hypercholesterolemia were significantly higher than in ACS patients. Some of these results, such as serum lipid levels and DBP, were similar to results from other studies. However, other risk factors, such as age and DM, were inconsistent with results from other studies.
Serum lipid levels are important risk factors for the development of both stable and acute CHD. 20 Cianflone et al showed that patients presenting with stable AP had developed more extensive atherosclerosis than those presenting with acute MI. 21 Acute coronary syndrome is plaque disruption with superimposed thrombosis 22 ; it may be the vulnerability of the plaque rather than the extent of coronary atherosclerosis. 23 Inflammatory cell activity, smoking, disturbed fibrinolysis, and hemodynamic factors have been suggested to lead to this vulnerability. 20 Smoking was a significant independent predictor of unheralded MI, 20 and cigarette smoking plays a role in the pathophysiology of plaque rupture. 24 smoking rates in ACS patients is consistent with the above results. Hypertension may lead to atherosclerosis through impairing endothelial function 26 and disrupt plaque through mechanical stress on the arterial wall. 20, 24 But some studies report that the prevalence of arterial hypertension was significantly higher in stable AP than in MI. 16 In our study, only DBP was significantly higher in non-ACS patients compared with ACS patients on increasing trends. This increasing trend was consistent with national-level results. 27, 28 In our study, non-ACS patients were older than ACS patients. This finding was inconsistent with other studies of ACS conducted with younger patients. 29, 30 This study found DM to be higher in non-ACS patients than in ACS patients, which is inconsistent with a study that showed proinsulin levels were independent predictors of unheralded MI. 20 Persons with DM are at increased risk of silent myocardial ischemia and MI. 31 The prevalence of DM has been increasing dramatically in recent decades. 28, 32 Because ACS is a heterogeneous condition that may comprise unstable AP, STEMI, and NSTEMI, we can understand that the results were heterogeneous. Further studies will need to be done that adjust for specific ACS disease type.
In our results, ACS patients used lipid-lowering drugs at a lower rate than did non-ACS patients before PCI; however, after PCI, that relationship was reversed, with ACS patients using more lipid-lowering drugs compared with non-ACS patients. We can understand this pattern of drug utilization. With non-ACS patients it can be possible to use more lipid-lowering and anti-inflammatory regimens that have been known to stabilize plaque. 33 Non-ACS patients are experiencing a chronic process, in stark contrast to ACS, which can have acute-onset characteristics.
Study Limitations
There are several limitations to our study. This study was a retrospective registry analysis from a single institution, which might limit its broad application. Although the results should be interpreted cautiously, 34 it represents the largest analysis of temporal trends of cvRfs in PCI patients over time. The study may be influenced by referral bias, selection bias, and verification bias, as the patients referred to tertiary centers may be a selected group, perhaps with more severe cases of CHD. Clinical characteristics and outcomes, other conventional risk factors, genetic factors, and related environmental factors such as diet were not included in this study. The current study was limited to hospitalized PCI cases; therefore, our findings should be limited to these populations and further studies are required to broaden the utility of these results. We are reliant on the quality of hospital coding in the Mayo Clinic PCI Registry, and to this extent, assessment of cvRFs closely relies on self-reporting of patients and available medical records. Finally, the characteristics of this study are purely descriptive, and confounding factors such as sex or age were not adjusted for in our analysis. Further studies are imperative to identify these differences and adjust for these limitations.
Conclusion
The FRS and 10-year CVD risk in PCI patients with and without ACS showed an improved trend over time driven by HDL-C and BP. Most cvRFs and their trends exhibited statistically significant differences between ACS and non-ACS patient cohorts. The ACS patients have more aggravated lipid profiles and a higher rate of current smoking than non-ACS patients, and the latter patients have more DM and hypertension than ACS patients. The ACS patients used fewer lipid-lowering drugs than did the non-ACS patients before PCI; however, this trend was reversed after PCI. These results suggest that a new risk-factor profile assessment might be needed for stratification of PCI patients according to ACS and non-ACS status.
